US 11,773,156 B2
Anti-hemagglutinin antibodies and methods of use thereof
Alina Baum, Pleasantville, NY (US); and Christos Kyratsous, Irvington, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed on Oct. 28, 2020, as Appl. No. 17/82,375.
Claims priority of provisional application 63/094,170, filed on Oct. 20, 2020.
Claims priority of provisional application 62/926,914, filed on Oct. 28, 2019.
Prior Publication US 2021/0171612 A1, Jun. 10, 2021
Int. Cl. C07K 16/10 (2006.01); A61P 31/16 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/1018 (2013.01) [A61K 45/06 (2013.01); A61P 31/16 (2018.01)] 21 Claims
 
1. An isolated recombinant antibody or antigen-binding fragment thereof that specifically binds to influenza B hemagglutinin (HA), wherein the antibody comprises (i) three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) comprising the amino acid sequence set forth in SEQ ID NO: 2; and (ii) three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within a light chain variable region (LCVR) comprising the amino acid sequence set forth in SEQ ID NO: 10.